Introduction
During the initial wave of the COVID-19 pandemic in early 2020, global scientific efforts focused primarily on understanding clinical progression and mortality rates. However, a significant gap existed in understanding the "health economics" of the disease—specifically, the direct medical costs associated with treating patients from admission to discharge. This retrospective study addresses this gap by analyzing 54 successfully treated patients at Henan Provincial People’s Hospital, linking clinical characteristics such as comorbidities and organ damage directly to medical billing data.
Methods
Researchers conducted a single-center descriptive study of 54 "cured" COVID-19 cases admitted between January and February 2020. Data was extracted from the Hospital Information System (HIS), allowing for a detailed breakdown of expenditures into four primary categories:
- Drug expenses: Including antivirals, antibiotics, and Traditional Chinese Medicine.
- Health services expenses: Covering nursing and room costs.
- Test expenses: Including laboratory work and CT scans.
- Medical material expenses: Covering PPE and specialized equipment.
Linear regression was employed to determine the correlation between total medical expenses and the number of comorbid chronic illnesses.
Clinical Characteristics and Timeline
The study cohort had an average age of 53.2 years, with an equal distribution between men and women. Chronic diseases were present in 57.4% of the patients. The most common clinical manifestations upon admission were fever (83.3%), cough (54.7%), and expectoration (51.9%).
A notable finding was the "10-day gap"—the median interval from the onset of signs and symptoms to hospital admission. This delay highlighted a significant window for potential community transmission during the early stages of the pandemic. Once hospitalized, approximately 80% of patients recovered within a two-week treatment period. The median interval from symptom onset to hospital discharge was 20.5 days.
Economic Analysis
The financial data revealed a modest median treatment cost for the majority of patients, but a highly skewed distribution driven by intensive critical care interventions.
The Impact of Comorbidities
The study identified a clear "inflection point" regarding comorbidities. While the median total medical expense for the general cohort was $2,579.60 (USD), this figure rose dramatically to $8,904.10 for patients with more than five comorbid conditions. This suggests that the complexity of underlying health issues is a primary driver of hospital resource consumption.
The Outlier Effect and Resource Allocation
The most striking economic insight was the concentration of costs among a few critically ill patients. The total expenditure for all 54 patients was approximately $504,663. However, the five most expensive cases accounted for 70.2% of this total. Specifically, one patient requiring Extracorporeal Membrane Oxygenation (ECMO) and Continuous Renal Replacement Therapy (CRRT) incurred costs of $212,542—representing over 42% of the entire cohort's total expenses.
Patients requiring CRRT and ECMO had significantly higher median expenses ($8,904.1) compared to those who did not ($2,163.6), a difference that was statistically significant (P < 0.001).
Conclusion and Limitations
This study provides a roadmap for hospital resource allocation by identifying the specific patient profiles—particularly those with multiple comorbidities—that drive the highest healthcare expenditures. It underscores that while the average case may be manageable, the "long tail" of critically ill patients requires disproportionate financial and material resources.
However, the study has limitations. The small sample size from a single center may limit generalizability. Furthermore, because the study focused exclusively on "successfully treated" patients, it does not account for the costs associated with mortality or the long-term economic burden of "Long COVID." Future research should expand to include broader societal costs, such as lost productivity and the long-term health expenditures of survivors with permanent organ damage.
Summary updated